Radical concurrent chemoradiotherapy and Durvalumab therapy for elderly patients

Radical concurrent chemoradiotherapy and Durvalumab therapy for elderly patients - Radical concurrent chemoradiotherapy and Durvalumab therapy for elderly patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053559

Enrollment

200

Registered

2024-03-18

Start date

2024-03-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with confirmed diagnosis of unresectable locally advanced non-small cell lung cancer undergoing cCRT Patients over 70 years old Patients for whom medical and prognostic information can be obtained from medical records

Exclusion criteria

Exclusion criteria: Patients who have requested not to participate in this study based on publicly available information Other patients deemed ineligible by the principal investigator

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Completion rate of radical concurrent chemoradiotherapy, treatment response at the end of radical concurrent chemoradiotherapy, overall survival, progression-free survival in the same regimen (carboplatin + paclitaxel weekly) group Rate of conversion to durvalumab therapy, reasons for nonconversion, completion rate, percentage of discontinuations, reasons for discontinuation, duration of treatment in discontinued cases, and details of adverse events during the course of treatment	—

Measure

Time frame

Completion rate of radical concurrent chemoradiotherapy, treatment response at the end of radical concurrent chemoradiotherapy, overall survival, progression-free survival in the same regimen (carboplatin + paclitaxel weekly) group Rate of conversion to durvalumab therapy, reasons for nonconversion, completion rate, percentage of discontinuations, reasons for discontinuation, duration of treatment in discontinued cases, and details of adverse events during the course of treatment

—

Countries

Japan

Contacts

Public ContactAtsuhiko Yatani

Kobe University Graduate School of Medicine Division of Respiratory Medicine, Department of Internal Medicine

ayatani@med.kobe-u.ac.jp078-382-5668

Outcome results